*ongoing trials - trial from www.clinicaltrials.gov*

# A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 - Phase 2 - Not yet recruiting

**Code:** NCT03969888 **Year:** 2019 **Date:** August 27, 2019 **Author:** AbbVie

### Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

### Participants

Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

### Interventions

Drug: ABBV-3067|Drug: Placebo ABBV-3067|Drug: ABBV-2222|Drug: Placebo ABBV-2222

### Outcome measures

Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Absolute change in sweat chloride (SwCl)|Absolute change in forced vital capacity (FVC)|Absolute change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Relative change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in forced vital capacity (FVC)

https://ClinicalTrials.gov/show/NCT03969888

### Keywords

Adult; Aminophenols; Anti-Bacterial Agents; CFTR Modulators; G551D-CFTR; Genetic Predisposition to Disease; pharmacological_intervention; Quinolones; VX-770; ivacaftor; GLPG2222; ABBV2222; GLPG3067; ABBV3067;